Lupeng Pharma Enrolls First Patient in Global Phase 3 ROCKET-CLL Trial of Fourth-Gen BTK Inhibitor Rocbrutinib vs. Pirtobrutinib
Lupeng Pharmaceutical Ltd. announced the enrollment of the first patient in its global Phase 3...
Eli Lilly’s Retatrutide Delivers Breakthrough Weight Loss Results in Phase 3 TRIUMPH-1 Trial for Obesity Treatment
Eli Lilly and Company (NYSE: LLY) announced positive topline results from the TRIUMPH-1 Phase 3...
Merck KGaA Launches Phase III PROCEADE-CRC-03 Trial for First-in-Class CEACAM5 ADC Precemtabart Tocentecan in Metastatic Colorectal Cancer
Merck KGaA (ETR: MRK) announced the initiation of the Phase III PROCEADE-CRC-03 study, evaluating the...
Astellas and MSD’s PADCEV-Keytruda Combination Receives Positive CHMP Opinion for Muscle-Invasive Bladder Cancer in EU
Astellas Pharma Inc. (TYO: 4503) announced that the Committee for Medicinal Products for Human Use...
Hansoh Pharma’s HS-10504 Receives NMPA Breakthrough Therapy Designation for Fourth-Generation EGFR Inhibitor in Resistant NSCLC
Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced that China’s Center for Drug Evaluation (CDE)...
Bayer’s Kerendia Receives FDA Priority Review for Expanded Indication in Type 1 Diabetes-Associated Chronic Kidney Disease
Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration (FDA) has accepted...
Gilead Sciences Launches Five-Year WHO Partnership to Accelerate Elimination of Visceral Leishmaniasis in High-Burden Regions
Gilead Sciences, Inc. (NASDAQ: GILD) announced a five-year strategic collaboration with the World Health Organization...
Johnson & Johnson Partners with Abu Dhabi DOH to Launch Global Surgical Intelligence Network Powered by Polyphonic Platform
Johnson & Johnson (J&J, NYSE: JNJ) announced a strategic alliance with the Abu Dhabi Department...
Eli Lilly Acquires Engage Biologics for $202M to Bolster Genetic Medicines Portfolio with Tethosome Platform
Eli Lilly and Company (NYSE: LLY) announced the acquisition of Engage Biologics, a preclinical-stage biotechnology...
Yangtze River Pharma Secures NMPA Approval for Fazamorexant – Next-Generation DORA for Insomnia Treatment
Yangtze River Pharmaceutical Group (YRPG) announced that China’s National Medical Products Administration (NMPA) has granted...
Boehringer Ingelheim and Sino Biopharmaceutical Secure NMPA Conditional Approval for Hernexeos in First-Line HER2-Mutant NSCLC With 76% Response Rate
Boehringer Ingelheim (BI) and Sino Biopharmaceutical Ltd (HKG: 1177) jointly announced that Hernexeos (zongertinib) has...
Jenscare’s LuX-Valve Plus Demonstrates 97.8% Efficacy in Tricuspid Regurgitation Reduction in Global EU TRINITY Study 12-Month Follow-Up
Jenscare Scientific Co., Ltd (HKG: 9877), a structural heart disease device manufacturer, announced 12-month follow-up...
Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network
Bayzed Health Group (HKG: 2609) announced a strategic partnership with two subsidiaries of fellow Chinese...
Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma
Transcenta Holdings Ltd (HKG: 6628) and its U.S. partner Inhibrx Biosciences, Inc. (NASDAQ: INBX) announced...
Sino Medical Sciences Secures EU Label Update for HT Supreme Stent, Enabling One-Month Dual Antiplatelet Therapy
Sino Medical Sciences Technology Inc. (SHA: 688108) announced European Union regulatory approval for a label...
Mabwell Bioscience Secures Second NMPA Approval for Denosu Biosimilar, Expanding Indication to Bone Metastases and Multiple Myeloma
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced it has received a second indication approval...
Pfizer’s 25-Valent Pneumococcal Vaccine Candidate Shows Superior Serotype 3 Response in Phase II Infant Study
Pfizer Inc. (NYSE: PFE) announced positive readouts from a Phase II clinical study evaluating its...
Medtronic to Acquire SPR Therapeutics for $650 Million, Expanding Chronic Pain Management Portfolio
Medtronic plc (NYSE: MDT) announced its intent to acquire SPR Therapeutics, Inc., a privately held...
BeOne Medicines Launches “One Save Changes Everything” Global Cancer Care Initiative, Partnering With Soccer Legend Tim Howard
BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly known as BeiGene, Ltd., today...
Bristol-Myers Squibb Partners With Anthropic to Deploy Claude AI Across Enterprise, Signaling Strategic Shift to Agentic Workflows
Bristol-Myers Squibb Company (BMS, NYSE: BMY) announced a strategic agreement with artificial intelligence pioneer Anthropic...